We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Royalty Rate Set In Boston, Cordis Stent Spat

Law360 (April 13, 2009, 12:00 AM EDT) -- Resolving all remaining issues in a seven-year dispute over stent patents, a federal judge has ruled that Boston Scientific Corp. must pay a 5.1 percent royalty rate on its sales of products infringing on Cordis Corp.'s patents.

The rate applies to catheters sold alone or as part of a stent delivery system, according to the order entered Thursday by U.S. District Judge Susan Illston in the U.S. District Court for the Northern District of California.

Boston Scientific and Johnson & Johnson's Cordis unit were unable to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.